Should I buy or sell Avinger stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avinger in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVGR shares. View AVGR analyst ratings or view top-rated stocks .

What is Avinger's stock price target for 2024?

1 brokers have issued twelve-month price objectives for Avinger's stock. Their AVGR share price targets range from $5.00 to $5.00. On average, they expect the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 47.9% from the stock's current price. View analysts price targets for AVGR or view top-rated stocks among Wall Street analysts .

How have AVGR shares performed in 2023?

Avinger's stock was trading at $16.2750 at the beginning of 2023. Since then, AVGR stock has decreased by 79.2% and is now trading at $3.38. View the best growth stocks for 2023 here .

Are investors shorting Avinger?

Avinger saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 4,500 shares, a decline of 70.4% from the October 31st total of 15,200 shares. Based on an average trading volume of 1,910,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.4% of the shares of the company are short sold. View Avinger's Short Interest .

When is Avinger's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024. View our AVGR earnings forecast .

How were Avinger's earnings last quarter?

Avinger, Inc. (NASDAQ:AVGR) issued its quarterly earnings data on Thursday, October, 26th. The medical device company reported ($2.92) earnings per share for the quarter, missing analysts' consensus estimates of ($2.85) by $0.07. The medical device company earned $1.82 million during the quarter, compared to the consensus estimate of $2.40 million. Avinger had a negative trailing twelve-month return on equity of 6,767.92% and a negative net margin of 225.61%.

When did Avinger's stock split?

Shares of Avinger reverse split on the morning of Wednesday, September 13th 2023. The 1-15 reverse split was announced on Wednesday, September 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Avinger own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avinger investors own include Bionano Genomics (BNGO) , Novan (NOVN) , Titan Pharmaceuticals (TTNP) , Matinas BioPharma (MTNB) , Zosano Pharma (ZSAN) , Organigram (OGI) , Onconova Therapeutics (ONTX) , ADMA Biologics (ADMA) , Aeterna Zentaris (AEZS) and Actinium Pharmaceuticals (ATNM) .

When did Avinger IPO?

(AVGR) raised $60 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Canaccord Genuity and Cowen and Company served as the underwriters for the IPO and Oppenheimer, BTIG and Stephens were co-managers.

How do I buy shares of Avinger?

Shares of AVGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Avinger Stock Price, News & Analysis (NASDAQ:AVGR)

$3.38

+0.47 (+16.15%)

(As of 12/4/2023 ET)

Compare

Today's Range: $2.90
▼
$3.49
50-Day Range: $2.85
▼
$7.61
52-Week Range: $2.78
▼
$24.30

Volume: 117,770 shs
Average Volume: 541,425 shs
Market Capitalization: $4.63 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Avinger MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 47.9% Upside
$5.00 Price Target
Short Interest: Healthy
0.37% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.85
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.59) to ($2.26) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Avinger has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.00, Avinger has a forecasted upside of 47.9% from its current price of $3.38.
Amount of Analyst Coverage
Avinger has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.37% of the float of Avinger has been sold short.
Short Interest Ratio / Days to Cover
Avinger has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Avinger has recently decreased by 70.39%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Avinger does not currently pay a dividend.
Dividend Growth
Avinger does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AVGR.

3.3

News and Social Media Coverage

News Sentiment
Avinger has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Avinger this week, compared to 1 article on an average week.
Search Interest
3 people have searched for AVGR on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Avinger insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.29% of the stock of Avinger is held by insiders.
Percentage Held by Institutions
Only 8.14% of the stock of Avinger is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Avinger are expected to grow in the coming year, from ($3.59) to ($2.26) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Avinger is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Avinger is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Avinger has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Avinger Stock (NASDAQ:AVGR)

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, including Ocelot and Tigereye, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is headquartered in Redwood City, California.

AVGR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AVGR Stock News Headlines

December 1, 2023 | benzinga.com

Avinger Stock (NASDAQ:AVGR) Dividends: History, Yield and Dates

October 27, 2023 | finance.yahoo.com

Avinger, Inc. (NASDAQ:AVGR) Q3 2023 Earnings Call Transcript

December 5, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

October 26, 2023 | finanznachrichten.de

Avinger, Inc.: Avinger Reports Third Quarter 2023 Results

October 26, 2023 | finance.yahoo.com

Avinger Reports Third Quarter 2023 Results

October 26, 2023 | finance.yahoo.com

Avinger (AVGR) Reports Q3 Loss, Lags Revenue Estimates

October 25, 2023 | benzinga.com

Avinger Earnings Preview

October 19, 2023 | finance.yahoo.com

Avinger to Announce Third Quarter 2023 Results on October 26

December 5, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

September 27, 2023 | finanznachrichten.de

Avinger, Inc.: Avinger Raises $5.3 Million via At-The-Market Facility

September 27, 2023 | finance.yahoo.com

Avinger Raises $5.3 Million via At-The-Market Facility

September 21, 2023 | benzinga.com

Thinking about buying stock in Neptune Wellness Solutions, Kezar Life Sciences, Avinger, Canopy Growth Corp, or Nio Inc?

September 20, 2023 | finanznachrichten.de

Avinger, Inc.: Avinger Initiates Full Commercial Launch of Tigereye ST Image-Guided CTO Crossing Device

September 20, 2023 | benzinga.com

What's Going On With Avinger Inc. Stock Today?

September 19, 2023 | seekingalpha.com

Avinger jumps 28%, enters ATM equity offering

September 19, 2023 | benzinga.com

Avinger Stock Is Soaring Again: What's Going On?

September 19, 2023 | benzinga.com

Nio, PayPal, Block, Tesla, Avinger: What You Need To Know About These Five Stocks Trending Today

September 18, 2023 | marketwatch.com

Avinger Shares Rise 64% After Commercial Launch of Tigereye ST

September 18, 2023 | msn.com

Why Is MedTech Firm Avinger Stock Trading Higher Today?

September 18, 2023 | finance.yahoo.com

Avinger Initiates Full Commercial Launch of Tigereye ST Image-Guided CTO Crossing Device

August 26, 2023 | money.usnews.com

Avinger Inc

August 25, 2023 | finance.yahoo.com

Unmasking the Value Trap: A Deep Dive into Avinger Inc (AVGR)

August 24, 2023 | finance.yahoo.com

Avinger Announces Presentations by Key Opinion Leaders at AMP (The Amputation Prevention Symposium) 2023

August 4, 2023 | finance.yahoo.com

Avinger Announces Conversion of 12% of CRG Term Debt into Equity

July 28, 2023 | msn.com

Avinger GAAP EPS of -$0.59 misses by $0.10, revenue of $2.04M misses by $0.26M

July 28, 2023 | markets.businessinsider.com

Avinger (AVGR) Receives a Buy from H.C. Wainwright

July 28, 2023 | finance.yahoo.com

Avinger Reports Second Quarter 2023 Results

See More Headlines

Receive AVGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avinger and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 10/26/2023
Today: 12/04/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/20/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AVGR
CUSIP: N/A
CIK: 1506928
Web: www.avinger.com
Phone: (650) 241-7900
Fax: 800-229-2696
Employees: 71
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.00
High Stock Price Target: $5.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +47.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($32.9056)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17,620,000.00
Net Margins: -225.61%
Pretax Margin: -225.61%
Return on Equity: -6,767.92%
Return on Assets: -87.99%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.85
Quick Ratio: 0.55

Sales & Book Value

Annual Sales: $8.27 million
Price / Sales: 0.56
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.36 per share
Price / Book: 0.40

Miscellaneous

Outstanding Shares: 1,370,000
Free Float: 1,311,000
Market Cap: $4.63 million
Optionable: Not Optionable
Beta: 1.30

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Jeffrey M. Soinski (Age 61)
President, CEO & Director
Comp: $605.15k
Mr. Nabeel P. Subainati (Age 39)
VP of Finance, Principal Financial Officer & Accounting Officer
Comp: $295.85k
Mr. Himanshu N. Patel (Age 63)
Chief Technology Officer
Comp: $423.09k
Mr. Keith Schaefer
Chief Operating Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AVGR Stock Analysis - Frequently Asked Questions

Should I buy or sell Avinger stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avinger in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVGR shares.
View AVGR analyst ratings or view top-rated stocks.
What is Avinger's stock price target for 2024?: 1 brokers have issued twelve-month price objectives for Avinger's stock. Their AVGR share price targets range from $5.00 to $5.00. On average, they expect the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 47.9% from the stock's current price.
View analysts price targets for AVGR or view top-rated stocks among Wall Street analysts.
How have AVGR shares performed in 2023?: Avinger's stock was trading at $16.2750 at the beginning of 2023. Since then, AVGR stock has decreased by 79.2% and is now trading at $3.38.
View the best growth stocks for 2023 here.
Are investors shorting Avinger?: Avinger saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 4,500 shares, a decline of 70.4% from the October 31st total of 15,200 shares. Based on an average trading volume of 1,910,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.4% of the shares of the company are short sold.
View Avinger's Short Interest.
When is Avinger's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our AVGR earnings forecast.
How were Avinger's earnings last quarter?: Avinger, Inc. (NASDAQ:AVGR) issued its quarterly earnings data on Thursday, October, 26th. The medical device company reported ($2.92) earnings per share for the quarter, missing analysts' consensus estimates of ($2.85) by $0.07. The medical device company earned $1.82 million during the quarter, compared to the consensus estimate of $2.40 million. Avinger had a negative trailing twelve-month return on equity of 6,767.92% and a negative net margin of 225.61%.

When did Avinger's stock split?: Shares of Avinger reverse split on the morning of Wednesday, September 13th 2023. The 1-15 reverse split was announced on Wednesday, September 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What other stocks do shareholders of Avinger own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Avinger investors own include Bionano Genomics (BNGO), Novan (NOVN), Titan Pharmaceuticals (TTNP), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Organigram (OGI), Onconova Therapeutics (ONTX), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS) and Actinium Pharmaceuticals (ATNM).
When did Avinger IPO?: (AVGR) raised $60 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Canaccord Genuity and Cowen and Company served as the underwriters for the IPO and Oppenheimer, BTIG and Stephens were co-managers.
How do I buy shares of Avinger?: Shares of AVGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AVGR) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial